Education
About Us
Working with TipRanks
Follow Us
Pharming Group (NL:PHARM)
:PHARM
Total Valuation
Pharming Group has a market cap or net worth of €906.92M. The enterprise value is €1.00B.
Market Cap€906.92M
Enterprise Value€1.00B
Share Statistics
Pharming Group has 701,404,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding701,404,050
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pharming Group’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.01%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.01%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee824.95K
Profits Per Employee6.25K
Employee Count404
Asset Turnover0.78
Inventory Turnover0.73
Valuation Ratios
The current PE Ratio of Pharming Group is 408.6. Pharming Group’s PEG ratio is -3.33.
PE Ratio408.6
PS Ratio3.10
PB Ratio4.37
Price to Fair Value4.37
Price to FCF23.69
Price to Operating Cash Flow19.43
PEG Ratio-3.33
Income Statement
In the last 12 months, Pharming Group had revenue of 333.28M and earned 2.53M in profits. Earnings per share was <0.01.
Revenue333.28M
Gross Profit292.97M
Operating Income17.11M
Pretax Income11.38M
Net Income2.53M
EBITDA27.05M
Earnings Per Share (EPS)<0.01
Cash Flow
In the last 12 months, operating cash flow was 50.18M and capital expenditures -720.00K, giving a free cash flow of 49.46M billion.
Operating Cash Flow50.18M
Free Cash Flow49.46M
Free Cash Flow per Share0.07
Dividends & Yields
Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.16
52-Week Price Change59.04%
50-Day Moving Average1.46
200-Day Moving Average1.24
Relative Strength Index (RSI)37.92
Average Volume (3m)19.18M
Important Dates
Pharming Group upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Pharming Group as a current ratio of 2.59, with Debt / Equity ratio of 41.78%
Current Ratio2.59
Quick Ratio2.03
Debt to Market Cap0.08
Net Debt to EBITDA-0.95
Interest Coverage Ratio1.06
Taxes
In the past 12 months, Pharming Group has paid 9.14M in taxes.
Income Tax9.14M
Effective Tax Rate0.80
Enterprise Valuation
Pharming Group EV to EBITDA ratio is 37.20, with an EV/FCF ratio of 23.09.
EV to Sales3.02
EV to EBITDA37.20
EV to Free Cash Flow23.09
EV to Operating Cash Flow22.75
Balance Sheet
Pharming Group has €153.15M in cash and marketable securities with €98.58M in debt, giving a net cash position of €54.57M billion.
Cash & Marketable Securities€153.15M
Total Debt€98.58M
Net Cash€54.57M
Net Cash Per Share€0.08
Tangible Book Value Per Share€0.33
Margins
Gross margin is 88.23%, with operating margin of 5.13%, and net profit margin of 0.76%.
Gross Margin88.23%
Operating Margin5.13%
Pretax Margin3.42%
Net Profit Margin0.76%
EBITDA Margin8.12%
EBIT Margin5.13%
Analyst Forecast
The average price target for Pharming Group is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast24.19%
EPS Growth Forecast99.16%